Imperial Petroleum stock falls after announcing $60M share offering
Investing.com - UBS has reiterated a Buy rating and $40.00 price target on Moderna (NASDAQ:MRNA) following the company’s Analyst Day presentation. The target represents nearly 80% upside from the current price of $22.36, with InvestingPro data showing the stock trading near its 52-week low of $22.32 and significantly below its Fair Value estimate.
The biotechnology company hosted the event to present pipeline progress and business strategy updates, outlining a strategic transition period focused on topline growth and diversifying beyond infectious diseases. According to InvestingPro data, Moderna holds more cash than debt on its balance sheet, providing financial flexibility for this transition despite burning through cash rapidly.
UBS highlighted several positive aspects of Moderna’s presentation, including disciplined cost management, potential revenue growth from respiratory vaccines, and pipeline prioritizations.
The firm’s analysis maintains focus on Moderna’s execution of its planned 2026 commercial ramp and upcoming oncology clinical readouts as key factors for the company’s performance.
UBS believes data from the INT expected in the third quarter of 2026 will serve as a key catalyst for the stock, while noting that prudent near-term financial execution could drive sentiment improvement for Moderna.
In other recent news, Moderna has secured a five-year term loan facility for up to $1.5 billion from Ares Management Credit Funds. This financing includes an initial draw of $600 million this quarter and has raised the company’s fiscal year 2025 cash guidance to between $7.1 billion and $7.6 billion. The company announced a three-year business strategy aiming for a 10% revenue increase in 2026 and plans to expand its seasonal vaccine franchise to potentially six approved products by 2028. Additionally, Moderna revealed plans for a $1 billion cost-saving initiative, which will be implemented equally in 2026 and 2027. Analysts from Needham have maintained a Hold rating on the stock, noting the financial flexibility provided by the new debt facility. Meanwhile, Leerink Partners raised its price target for Moderna to $18 from $15 but maintained an Underperform rating. RBC Capital adjusted its price target to $25 from $28, citing the company’s cost-cutting plans. These developments come as Moderna aims to reach cash breakeven by 2028, leveraging cash from its marketed products to fund oncology and rare disease programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.